Citigroup Inc Verona Pharma PLC Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Verona Pharma PLC stock. As of the latest transaction made, Citigroup Inc holds 1,281 shares of VRNA stock, worth $57,696. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,281

Previous 1,477 13.27%

Holding current value

$57,696

Previous $21,000 71.43%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$15.46 - $30.16 $3,030 - $5,911	-196 Reduced 13.27%	1,281 $36,000
Q2 2024 Aug 12, 2024	BUY	$11.48 - $17.02 $14,120 - $20,934	1,230 Added 497.98%	1,477 $21,000
Q1 2024 May 10, 2024	SELL	$15.3 - $20.24 $14,703 - $19,450	-961 Reduced 79.55%	247 $3,000
Q4 2023 Feb 09, 2024	BUY	$11.94 - $20.47 $4,489 - $7,696	376 Added 45.19%	1,208 $24,000
Q3 2023 Nov 09, 2023	SELL	$16.3 - $22.09 $4,857 - $6,582	-298 Reduced 26.37%	832 $13,000
Q2 2023 Aug 10, 2023	BUY	$19.41 - $23.43 $7,899 - $9,536	407 Added 56.29%	1,130 $23,000
Q1 2023 May 11, 2023	SELL	$18.06 - $25.27 $1,029 - $1,440	-57 Reduced 7.31%	723 $14,000
Q4 2022 Feb 09, 2023	BUY	$9.84 - $26.13 $7,675 - $20,381	780 New	780 $20,000
Q2 2022 Aug 10, 2022	SELL	$3.55 - $5.06 $1.31 Million - $1.87 Million	-369,008 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$4.82 - $6.98 $1.78 Million - $2.58 Million	369,008 New	369,008 $1.84 Million
Q4 2021 Feb 10, 2022	SELL	$3.91 - $7.08 $1.94 Million - $3.51 Million	-495,446 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$5.29 - $6.35 $2.62 Million - $3.15 Million	495,446 New	495,446 $2.72 Million

Others Institutions Holding VRNA

# of Institutions

167

Shares Held

68.7M

Call Options Held

704K

Put Options Held

685K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.75B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account